Hansoh Pharmaceutical (HKG:3692) said HS-20093 for injection was included in the priority review and approval procedure of China's National Medical Products Administration, a Tuesday bourse filing showed.
The inclusion came due to positive results from a phase III trial of the drug for the treatment of osteosarcoma patients aged 12 years and above who have failed at least two prior lines of therapy.